TiGenix NV Stock

Stocks

18-03-28	Takeda Pharmaceutical : Drugmaker Shire soars as Japan's Takeda considers bid	RE
18-02-01	Takeda Pharmaceutical : Japan's Takeda hikes outlook on cancer drug sales, third quarter profit jumps	RE
18-01-22	Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	RE
18-01-08	Takeda Pharmaceutical : Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid	RE
18-01-08	Takeda Pharmaceutical : $11 billion biotech binge fuels forecasts of 2018 M&A surge	RE
12-10-04	GALAPAGOS : Maturing Belgian biotechs outshine European peers	RE

18-07-31	TiGenix : Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period (EN - NL - FR - ES)	PU
18-07-31	TiGenix : Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period	GL
18-07-23	TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007	GL
18-07-06	TiGenix : Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid in respect of TiGenix and Commencement of Simplified Squeeze-out and Intention to Delist the ADSs from Nasdaq, Terminate the ADS Facility and Terminate TiGenix’s U.S. Reporting Obligations (EN – NL – FR – ES)	PU
18-07-06	TiGenix : Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid	GL

18-07-31	TiGenix : Takeda termine son acquisition de TiGenix suite à l'expiration de la période de retrait
18-07-23	Le Graph du Jour : 29% des biotechs en territoire positif depuis leur IPO sur Euronext
18-07-06	TiGenix : Takeda et TiGenix annoncent les résultats de la deuxième période d'acceptation pour l'offre publique d'acquisition volontaire et conditionnelle de TiGenix
18-06-13	TiGenix : annonce un changement dans son conseil d'administration et son équipe de direction
18-06-06	TiGenix : Takeda et TiGenix annoncent les résultats de la première période d'acceptation pour l'offre publique d'acquisition volontaire et conditionnelle de TiGenix et le début de la deuxième période d'accep...

Manager	Title	Age	Since
Wilfried Dalemans CTO	Chief Tech/Sci/R&D Officer	68	-
Koen Huygens PRN	Corporate Officer/Principal	-	2001-06-30
Julian Panes PRN	Corporate Officer/Principal	-	-

Director	Title	Age	Since
Sebastian Wehle BRD	Director/Board Member	-	2018-06-14
Jean Stephenne CHM	Chairman	77	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TIGENIX NV	-.--%	-.--%	-	-	0
WUXI APPTEC CO., LTD.	+0.65%	-3.56%	+33.53%	+60.50%	63.48B
ARGENX SE	+1.76%	+1.27%	+11.82%	+82.12%	54.55B
LONZA GROUP AG	-1.09%	+0.80%	+10.24%	+101.80%	53.59B
IQVIA HOLDINGS INC.	+1.76%	+0.05%	+26.89%	+56.23%	44.75B
BEONE MEDICINES AG	+2.11%	-3.19%	+18.08%	+100.50%	41.62B
REVOLUTION MEDICINES, INC.	+0.08%	-4.01%	+220.59%	+916.29%	39.91B
CELLTRION, INC.	+0.64%	-3.85%	+11.71%	+45.57%	32.47B
GENMAB A/S	+29.06%	+47.63%	+107.12%	+94.27%	26.7B
WUXI BIOLOGICS (CAYMAN) INC.	+3.72%	-7.45%	+24.25%	-2.99%	23.36B
Average	+3.87%	-0.42%	+51.58%	+161.59%	42.27B
Weighted average by Cap.	+2.98%	-0.29%	+47.02%	+160.28%